OniX OnPoint Issue #48: Growth Differentiation Factor 15 (GDF-15) in Disease Pathophysiology and Therapeutic Innovation

Translational Insights from Biomarker Discovery to Targeted Interventions in Neurology, Oncology, and Metabolic Disorders

Growth Differentiation Factor 15 (GDF-15) is rapidly emerging as one of the most intriguing and versatile molecules in translational medicine. Once a niche biomarker, GDF-15 is now at the heart of a scientific renaissance, linking acute brain injury to cardiac dysfunction, orchestrating appetite and nausea, and offering new hope for metabolic and fibrotic diseases. In this edition of OniX OnPoint, we spotlight the latest research, clinical advances, and biotech innovation driving the GDF-15 revolution—from bench to bedside.

Table of Contents

1. Feature Spotlight: Stroke-Induced Myocardial Dysfunction (SMOG-15)

2. Central MIC-1 Signaling: Appetite, Nausea, and Emesis

3. Exercise, GDF-15, and Diabetes: The Muscle-Pancreas Crosstalk

4. Pyroptosis and Inflammation: GDF-15 in Periodontal Ligament Biology

5. Mitochondrial Dysfunction in DMD: The Dp71 Connection

6. GDF-15 in Pediatric Cancer: Muscle Integrity and Fibrosis

7. Ocular Innovation: GDF-15 for Proliferative Vitreoretinopathy

8. GDF-15 Analogs: The Next Wave in Obesity Therapeutics

9. Startups & Biotech: Pioneering GDF-15 and Metabolic Innovation

10. Discussion: GDF-15 – Biomarker, Target, or Both?